Hotline:4006-508-908

Services
Cancer Type Plan Guiding Chemotherapy/
Targeted Drugs
Guiding Significance Genes to be Detected
Non-small cell lung cancer Targeting Erlotinib
Gefitinib
Icotinib

Afatinib
Efficacy EGFR mutation
KRAS mutation
BIM polymorphism
PIK3CA mutation

MET amplification
EML4-ALK rearrangement
BRAF mutation
Crizotinib Efficacy EML4-ALK merging
ROS1 rearrangement
MET ampification
Ceritinib Efficacy EML4-ALK rearrangement
Bevacizumab Efficacy VEGF expression
VEGFR1 expression
VEGFR2 expression
Cabozantinib Efficacy KIF5B-RET rearrangement
Vemurafenib
Dabrafenib
Efficacy BRAF mutation
Chemotherapy Cisplatin
Carboplatin
Efficacy GSTP1 polymorphism
ERCC1 expression
Gemcitabine Efficacy RRM1 expression
Pemetrexed Efficacy TYMS expression
Paclitaxel
Docetaxel
Navelbine
Efficacy TUBB3 expression
BRCA1 expression
Toxicity CYP3A5*3 polymorphism
Etoposide Efficacy TOP2A expression
Irinotecan Toxicity UGT1A1*28 polymorphism
UGT1A1*6 polymorphism
Ifosfamide Efficacy CYP2C9*2 polymorphism
CYP2C9*3 polymorphism

©Beijing ACCB Biotech Company Limited     All Rights Reserved Jing ICP Registration No05018742-1     Site map